Efficacy and safety of fezolinetant in the treatment of moderate to severe vasomotor symptoms in women for whom hormone therapy is considered inappropriate
Klinická farmakologie a farmacie · 30.10.2025 · 39 (3) · 174-180
DOI: 10.36290/far.2025.062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinická farmakologie a farmacie, erschienen am 30.10.2025. Verfasst von Marek Lapka. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Lapka, M. (2025). Efficacy and safety of fezolinetant in the treatment of moderate to severe vasomotor symptoms in women for whom hormone therapy is considered inappropriate. Klinická farmakologie a farmacie, 39(3), 174-180. https://doi.org/10.36290/far.2025.062
Vancouver
Lapka M. Efficacy and safety of fezolinetant in the treatment of moderate to severe vasomotor symptoms in women for whom hormone therapy is considered inappropriate. Klinická farmakologie a farmacie. 2025;39(3):174-180. doi:10.36290/far.2025.062
BibTeX
@article{Lapka2025,
author = {Lapka, Marek},
title = {Efficacy and safety of fezolinetant in the treatment of moderate to severe vasomotor symptoms in women for whom hormone therapy is considered inappropriate},
journal = {Klinická farmakologie a farmacie},
year = {2025},
volume = {39},
number = {3},
pages = {174--180},
doi = {10.36290/far.2025.062}
}
EUVIMED